Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Oyster Point Pharma, Inc. was a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for ophthalmic diseases. Their flagship product, TYRVAYA® (varenicline solution) Nasal Spray, gained FDA approval as the first and only nasal spray for treating the signs and symptoms of dry eye disease. Founded in 2015, Oyster Point Pharma made significant contributions to eye care before its acquisition by Viatris Inc. in January 2023. This strategic acquisition integrated Oyster Point's promising pipeline and its commercialized product, TYRVAYA®, into Viatris's expanding global healthcare portfolio, particularly bolstering its new ophthalmology franchise.
The Princeton headquarters served as the central locus for Oyster Point Pharma's corporate operations, research and development oversight, clinical program management, and commercialization strategy.
Located within the Carnegie Center office park, the headquarters offered a professional environment conducive to biotech operations. Specific unique architectural details of their leased suite are not widely publicized, with the emphasis likely on functional office and support spaces for R&D.
Oyster Point Pharma was known for fostering a dynamic, innovative, and collaborative work environment. The culture was mission-driven, with employees dedicated to advancing scientific research and bringing novel treatments to patients suffering from ocular diseases.
The Princeton, New Jersey headquarters was strategically significant due to its location within a dense ecosystem of pharmaceutical companies, research institutions, and a skilled talent pool, facilitating collaborations and growth.
Before its acquisition by Viatris, Oyster Point Pharma's operational and commercial focus was predominantly on the United States market, highlighted by the FDA approval and launch of TYRVAYA® Nasal Spray. While its research and development efforts considered global scientific advancements, its direct commercial presence and infrastructure were concentrated in the U.S. Following the acquisition, its products and development pipeline became part of Viatris's extensive global operations.
902 Carnegie Center, Suite 260
Princeton
New Jersey
USA
Address: N/A
N/A
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Oyster Point Pharma' leadership includes:
Oyster Point Pharma has been backed by several prominent investors over the years, including:
In the 12-18 months leading up to and including its acquisition by Viatris in January 2023, Oyster Point Pharma experienced key executive appointments and subsequent departures as part of the integration. Notably, a new CMO and CLO were hired in mid-2022. The acquisition resulted in the transition or departure of most of the legacy Oyster Point Pharma executive team.
Discover the tools Oyster Point Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition by Viatris, Oyster Point Pharma typically utilized common corporate email formats. The most prevalent pattern was [first_initial][last]@oysterpointrx.com. These formats are now historical as employee communications are managed through Viatris.
[first_initial][last]@oysterpointrx.com
Format
jdoe@oysterpointrx.com
Example
75%
Success rate
Oyster Point Pharma / PR Newswire • October 18, 2021
Oyster Point Pharma announced U.S. FDA approval for TYRVAYA (varenicline solution) Nasal Spray for treating the signs and symptoms of dry eye disease, marking it as the first and only nasal spray for this indication....more
Oyster Point Pharma / Business Wire • November 16, 2021
Oyster Point Pharma announced the U.S. commercial launch of TYRVAYA™ (varenicline solution) Nasal Spray, making the innovative treatment for dry eye disease available to patients by prescription....more
Viatris Inc. / PR Newswire • November 7, 2022
Viatris Inc. announced a definitive agreement to acquire Oyster Point Pharma as part of a strategy to establish a new ophthalmology franchise. The deal was valued at approximately $415 million in cash upfront for Oyster Point Pharma shareholders....more
Viatris Inc. / Business Wire • January 4, 2023
Viatris Inc. announced the successful completion of its acquisition of Oyster Point Pharma, Inc. This transaction officially integrated Oyster Point's assets, including TYRVAYA®, into Viatris, launching Viatris's new ophthalmology franchise....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Oyster Point Pharma, are just a search away.